Over the last decade, wehave demonstrated that the 1,4-dioxanenucleus represents a bioversatile carrier of ligands interacting withdifferent receptor systems,31−40 including D2-like receptors.41 In particular, two properly substituted 1,4-dioxane compounds endowedwith the fruitful multitarget combination of 5-HT1AR/D4R agonism and D2R/D3R/5-HT2AR antagonism (compound 1) or D2R/D3R/D4R/5-HT1AR agonism (compound 2) have been discovered as potential starting points to develop newpharmacological tools for schizophrenia and PD therapy, respectively41 (Figure 2). This evidence concerns the gene DRD2 and schizophrenia.